Fig. 2From: A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumorsStudy design. Abbreviations: CT, computed tomography; PD, progressive disease; EoS, End of Study; FUP, follow upBack to article page